Affiliation:
1. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
2. Department of Radiation Oncology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
3. Division of Hematology and Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
Abstract
AbstractCD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment for patients with relapsed/refractory large B‐cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET/CT) parameters on the CAR T‐related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre‐ and post‐CAR T metabolic parameters on survival and toxicities following CAR T‐cell therapy. Fifty‐nine patients with PET/CT scans done pre‐and post‐CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19‐targeted CAR T‐cell therapy. The median follow‐up was 10.7 months [interquartile range (IQR): 2.6–25.5 months]. The overall response (complete response‐CR and partial response) and CR rates post‐CAR T were 76% (n = 45) and 53% (n = 31), respectively. On univariate analysis, low pre‐CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post‐CAR T (OR = 4.7, p = 0.01, OR = 9.5, p = 0.03, respectively) and CR post‐CAR T (OR = 12.4, p = 0.0004, OR = 10.9, p = 0.0001, respectively). High TLG pre‐CAR T was correlated with cytokine release syndrome (CRS, OR = 3.25, p = 0.04). High MTV pre‐CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR = 4.3, p = 0.01), and high SUV pre‐CAR T was associated with grade 3–4 neurological events (OR = 12, p = 0.01). High MTV/TLG/SUVmax post‐CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre‐CAR T (HR = 2.4, p = 0.03), age ≥60 (HR = 2.7, p = 0.03), and bulky disease (≥5 cm) at the time of apheresis (HR = 2.5, p = 0.02) were identified to be independent prognostic factors for inferior PFS. High MTV post‐CAR T was identified as the most prognostic factor associated with inferior OS.
Subject
Cancer Research,Oncology,Hematology,General Medicine